Compounds > omeprazole

omeprazole and alendronate

omeprazole has been researched along with alendronate in 12 studies

Research

Studies (12)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (25.00)	18.2507
2000's	4 (33.33)	29.6817
2010's	5 (41.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Mochizuki, T; Nemoto, R; Okabe, K; Satou, S	1
Hussar, DA	1
Girelli, CM; Reguzzoni, G; Rocca, F	1
Beergabel, M; Gottesfeld, F; Keter, D; Lurie, Y; Malnick, SD; Walpart, A	1
Arbak, S; Dülger, GA; Ersoy, Y; Goren, FO; Sener, G; Ulusoy, NB	1
Bodde, EW; Jansen, JA; Kowalski, RS; Spauwen, PH	1
Cottrell, JA; Gundlapalli, R; Kapadia, R; O'Connor, JP; Schachter, D; Vales, FM; Wadsworth, S	1
Brandt, NJ; Stefanacci, RG	1
Cegieła, U; Folwarczna, J; Nowińska, B; Pytlik, M	1

Reviews

2 review(s) available for omeprazole and alendronate

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
[Alendronate-induced esophagitis. A report of 2 cases]. Recenti progressi in medicina, 1997, Volume: 88, Issue:5 Topics: Alendronate; Esophagitis; Female; Humans; Middle Aged; Omeprazole; Osteoporosis, Postmenopausal; Sucralfate; Time Factors	1997

Other Studies

10 other study(ies) available for omeprazole and alendronate

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6 Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics	2010
Response of MBT-2 bladder carcinoma-induced osteolysis to various agents. Cancer, 1992, May-01, Volume: 69, Issue:9 Topics: Alendronate; Animals; Bone Neoplasms; Bone Resorption; Calcitonin; Cyclosporine; Diphosphonates; Female; Mice; Mice, Inbred C3H; Mice, Nude; Neoplasm Transplantation; Omeprazole; Osteoclasts; Osteolysis; Urinary Bladder Neoplasms	1992
New therapeutic agents marketed in 1995. Pennsylvania medicine, 1996, Volume: 99, Issue:7 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acarbose; Alendronate; Anti-Inflammatory Agents; Anti-Ulcer Agents; Carbonic Anhydrase Inhibitors; Drug Approval; Enzyme Inhibitors; Hypoglycemic Agents; Lansoprazole; Metformin; Omeprazole; Pregnadienes; Sulfonamides; Thiophenes; Trisaccharides; United States; United States Food and Drug Administration	1996
Nonhealing gastric ulcer caused by chronic alendronate administration. MedGenMed : Medscape general medicine, 2002, May-22, Volume: 4, Issue:2 Topics: Abdominal Pain; Aged; Alendronate; Anti-Ulcer Agents; Bone Resorption; Drug Administration Schedule; Female; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Osteoporosis, Postmenopausal; Postprandial Period; Stomach Ulcer	2002
Protective effect of melatonin and omeprazole against alendronat-induced gastric damage. Digestive diseases and sciences, 2005, Volume: 50, Issue:8 Topics: Administration, Oral; Alendronate; Animals; Anti-Ulcer Agents; Antioxidants; Fasting; Female; Gastric Acidity Determination; Gastrointestinal Diseases; Injections, Intraperitoneal; Male; Melatonin; Omeprazole; Rats	2005
No increased bone formation around alendronate or omeprazole loaded bioactive bone cements in a femoral defect. Tissue engineering. Part A, 2008, Volume: 14, Issue:1 Topics: Alendronate; Animals; Bone Cements; Bone Density; Bone Density Conservation Agents; Enzyme Inhibitors; Female; Femur; Inflammation; Omeprazole; Osteogenesis; Rabbits; Time Factors; Tomography, X-Ray Computed	2008
Osteogenic activity of locally applied small molecule drugs in a rat femur defect model. Journal of biomedicine & biotechnology, 2010, Volume: 2010 Topics: Alendronate; Animals; Bone Density; Disease Models, Animal; Femur; Lovastatin; Male; Omeprazole; Organ Size; Osteogenesis; Rats; Rats, Sprague-Dawley; Wound Healing; X-Ray Microtomography	2010
Discontinuation of unnecessary medications in older adults. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2011, Volume: 26, Issue:11 Topics: Aged; Aged, 80 and over; Alendronate; Anti-Ulcer Agents; Antihypertensive Agents; Assisted Living Facilities; Bone Density Conservation Agents; Case Management; Diabetes Mellitus; Drug Therapy; Evidence-Based Medicine; Guidelines as Topic; Hepatitis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Lisinopril; Longevity; Male; Omeprazole; Osteoporosis; Palliative Care; Pharmacists; Precision Medicine; Simvastatin	2011
Proton pump (H+/K+-ATPase) inhibitors weaken the protective effect of alendronate on bone mechanical properties in estrogen-deficient rats. Pharmacological reports : PR, 2012, Volume: 64, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Drug Interactions; Estrogens; Female; Femur; Omeprazole; Ovariectomy; Pantoprazole; Proton Pump Inhibitors; Rats; Rats, Wistar; Tibia	2012